Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05867420 · ClinicalTrials.gov registry record · Phase 1

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A Phase 1 study of Advanced Solid Tumors, sponsored by AskGene Pharma.

Recruiting
Registry status
Phase 1
Development phase
594
Enrollment target
4
Study locations

NCT05867420 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by AskGene Pharma. The registered enrollment target is 594 participants, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (205% higher). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05867420, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by AskGene Pharma.

RECRUITING
Registry status
Phase 1
Development phase
594 participants
Enrollment target
4
Study locations

Study Summary

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Docetaxel
  • DRUG Fruquintinib
  • BIOLOGICAL ASKG915
  • DRUG Paclitaxel + Bevacizumab

Study Locations (4)

New York

  • Columbia University Irving Medical Center - New York

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Beijing Municipality

  • Peking University Cancer Hospital - Beijing

Shanghai Municipality

  • Fudan University Shanghai Cancer Center - Shanghai

Trial Details

FieldValue
Enrollment Target 594 participants
Start Date 2023-08-02
Est. Completion 2028-06-30
Phase Phase 1

Sponsor

AskGene Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05867420

The ClinicalTrials.gov registry entry for NCT05867420 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (205% higher). The listed sponsor is AskGene Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT05867420 reports 4 study locations spanning 4 distinct geographic areas - top geographies include New York, Pennsylvania, Beijing Municipality.

Frequently Asked Questions

What is clinical trial NCT05867420 about?

NCT05867420 is a clinical study titled "A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.". The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

What is the current status of trial NCT05867420?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 594 participants. The study started on 2023-08-02. Estimated completion is 2028-06-30.

What conditions does trial NCT05867420 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT05867420?

The interventions under investigation include: Docetaxel (DRUG), Fruquintinib (DRUG), ASKG915 (BIOLOGICAL), Paclitaxel + Bevacizumab (DRUG).

Who is sponsoring clinical trial NCT05867420?

This trial is sponsored by AskGene Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05867420 being conducted?

This trial has 4 study locations across New York, Pennsylvania, Beijing Municipality, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.